EDISON, N.J., Oct. 6, 2015 /PRNewswire/
-- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV)
("ContraVir" or the "Company"), a biopharmaceutical company focused
on the development and commercialization of targeted antiviral
therapies, today announced that it intends to offer shares of its
common stock and warrants to purchase shares of its common stock in
an underwritten public offering. The offering is subject to
market conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Laidlaw & Company (UK) Ltd. is the sole book-running manager
for the offering.
A shelf registration statement on Form S-3 relating to the
securities was filed with the Securities and Exchange Commission
and is effective. A preliminary prospectus supplement relating to
the offering will be filed with the SEC and will be available on
the SEC's web site at http://www.sec.gov. Electronic copies of the
preliminary prospectus supplement relating to the offering, when
available, may be obtained from the offices of Laidlaw &
Company (UK) Ltd., 546 Fifth Avenue, 5th Floor,
New York, NY, 10036, telephone:
212-953-4900 or by email at syndicate@laidlawltd.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About ContraVir Pharmaceuticals, Inc.:
ContraVir is a biopharmaceutical company focused on the
discovery and development of targeted antiviral therapies with two
candidates in mid-to-late stage clinical development. ContraVir's
lead clinical drug, FV-100, is an orally available nucleoside
analogue prodrug that is being developed for the treatment of
herpes zoster, or shingles, which is currently in Phase 3 clinical
development. In addition to direct antiviral activity, FV-100
has demonstrated the potential to reduce the incidence of
debilitating shingles-associated pain known as post-herpetic
neuralgia (PHN) in a Phase 2 clinical study. ContraVir is also
developing CMX157, a highly potent analog of the successful
antiviral drug tenofovir, for the Hepatitis B virus (HBV). CMX157's
novel structure results in decreased circulating levels of
tenofovir, lowering systemic exposure and thereby reducing the
potential for renal side effects.
Forward-looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding the proposed public offering from the offering. The
offering is subject to market and other conditions and there can be
no assurance as to whether or when the offering may be completed or
as to the actual size or terms of the offering. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including
market conditions, risks associated with the cash requirements of
our business and other risks detailed from time to time in our
filings with the Securities and Exchange Commission, and represent
our views only as of the date they are made and should not be
relied upon as representing our views as of any subsequent date. We
do not assume any obligation to update any forward-looking
statements.
CONTACT:
Tiberend Strategic Advisors, Inc.
Tirth Patel (investors)
tpatel@tiberend.com; (212) 375-2681
Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/contravir-pharmaceuticals-inc-announces-proposed-public-offering-of-common-stock-and-warrants-to-purchase-common-stock-300155245.html
SOURCE ContraVir Pharmaceuticals, Inc.